Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,599 recruiting studies in this area right now.
By phase
- Not applicable4,683
- Phase 21,187
- Phase 1568
- Phase 3457
- Phase 1/Phase 2366
- Phase 4228
- Phase 2/Phase 3110
Top conditions
- Colorectal Cancer478
- Pancreatic Cancer287
- Gastric Cancer283
- Hepatocellular Carcinoma256
- Esophageal Cancer189
- Rectal Cancer168
- Breast Cancer146
- Crohn Disease134
- Ulcerative Colitis129
- Colon Cancer114
- Hepatocellular Carcinoma (HCC)112
- Liver Cancer99
- Lung Cancer95
- Inflammatory Bowel Diseases94
- Pancreas Cancer91
- Ovarian Cancer89
- Esophageal Squamous Cell Carcinoma86
- Cystic Fibrosis77
Leading sponsors
- Fudan University101
- Sun Yat-sen University85
- Mayo Clinic75
- Second Affiliated Hospital, Zhejiang University, School of Medicine56
- Chinese University of Hong Kong55
- M.D. Anderson Cancer Center55
- Assistance Publique - Hôpitaux de Paris53
- Sixth Affiliated Hospital, Sun Yat-sen University51
- National Cancer Institute (NCI)49
- National Taiwan University Hospital45
Where studies are running
- California438
- Arizona189
- Texas140
- Alabama129
- Florida128
- New York120
- Massachusetts119
- Maryland88
- Ohio79
- Illinois69
Recruiting studies7,599 total
- NCT07556640RecruitingPhase 2
Drug combination for stomach cancer with abdominal spread
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
Shanghai, Huangpu DistrictAges 18 years+ - NCT07559474RecruitingPhase 1
Safety Study of INCB123667 in Adults With Liver Damage
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
Chandler, ArizonaAges 18–80 - NCT07551362RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Gastric Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Shenzhen, GuangdongAges 18–75 - NCT07555483RecruitingPhase 3
Weekly injection vs IV infusion for alpha-1 antitrypsin deficiency
This trial tests whether a new weekly injection form of alpha-1 antitrypsin replacement therapy (a protein your body lacks) works as well as the standard IV infusion you may currently receive. The goal is to offer a more convenient treatment option for people with alpha-1 antitrypsin deficiency (a genetic lung condition).
Birmingham, AlabamaAges 18–80 - NCT07556913Recruiting
Safety study of elafibranor medicine during pregnancy
This study tracks the safety of a medicine called elafibranor when taken before or during pregnancy. Researchers want to understand how the medicine affects pregnant people and their babies to help keep both safe.
Wilmington, North CarolinaAges Any age - NCT07552805Recruiting
Home monitoring device after major digestive surgery
This study tests a wearable patch called Multisense that monitors your health at home after major gastrointestinal surgery. It's designed to catch problems early so you can stay safe and avoid returning to the hospital.
Nice, Alpes-MaritimesAges 18 years+ - NCT07554456RecruitingPhase 2/Phase 3
New Drug Combination for Advanced Esophageal Cancer
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT07559175RecruitingPhase 2
A new enzyme treatment for pancreatic insufficiency
This study tests a new pancreatic enzyme medicine (called NHS7108) for people with exocrine pancreatic insufficiency (EPI). EPI means your pancreas doesn't make enough enzymes to break down food properly. The study aims to see if this new medicine is safe and works well to help your body absorb nutrients.
Scottsdale, ArizonaAges 18–85 - NCT06542588RecruitingPhase 2
Short radiation plus chemo and immunotherapy for rectal cancer
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT06740903RecruitingPhase 2/Phase 3
Comparing two drugs for pain control in gallbladder surgery
This study compares two medications, dexmedetomidine and lignocaine, to see which works better for pain management during and after laparoscopic gallbladder removal. It may help improve comfort and recovery for people having this surgery.
Sahiwal, Punjab ProvinceAges 20–70 - NCT06281678RecruitingPhase 2
Study of IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
San Francisco, CaliforniaAges 18 years+ - NCT05729438Recruiting
Nutritional assessment in people with liver cirrhosis
This study focuses on assessing nutrition in adults living with liver cirrhosis. The goal is to understand nutritional needs and how assessment may support care.
Bucharest, București - Sector1Ages 18–75 - NCT06699433Recruiting
AI virtual pediatric patient training for primary care doctors
This trial uses artificial intelligence to create virtual standardized pediatric patients. It helps train doctors who work in primary care settings, like community health centers and clinics.
Guiyang, GuizhouAges Any age - NCT03866525RecruitingPhase 1/Phase 2
Test an oncolytic virus treatment for solid tumors
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
Beijing, Beijing MunicipalityAges 18–75 - NCT05359939Recruiting
MRI, CT, and PET scans compared for liver cancer
This study compares different scan types (MRI, CT, and two PET scans) in people with hepatocellular carcinoma (a primary liver cancer). It may help doctors figure out which scan gives the most useful information for diagnosis and treatment planning.
AarhusAges 18 years+ - NCT07549113Recruiting
Preoperative prep methods for large abdominal wall hernias
This trial compares different ways to prepare your body before surgery to repair a large hernia (bulge in your abdominal wall). The goal is to find the best approach to help you heal well after surgery.
Krasnodar, Krasnodarskiy KrayAges 18 years+ - NCT07549100Recruiting
Tislelizumab plus chemotherapy for advanced esophageal cancer
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
Jinan, ShandongAges 18–75 - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+ - NCT07545772RecruitingPhase 2
Testing Brenipatide for Constipation-Focused IBS
This trial tests a new medicine called brenipatide to see if it can help people with IBS-C (irritable bowel syndrome with constipation). The study focuses on whether the drug reduces belly pain and improves bowel movements in people whose main symptom is hard or infrequent stools.
Mesa, ArizonaAges 18–75 - NCT07547553RecruitingPhase 1/Phase 2
HH-009 for Advanced Liver Cancer with FGF19 Marker
This trial tests a new drug called HH-009 for advanced or inoperable liver cancer (hepatocellular carcinoma, or HCC) that has a specific genetic marker called FGF19. The drug is designed to target this marker and may help slow or shrink the cancer in people whose disease has gotten worse despite previous treatment.
Bengbu, AnhuiAges 18–75 - NCT07545356RecruitingPhase 1
Testing KIVU-305 for Advanced Solid Tumors
This study tests a new cancer drug called KIVU-305 in people with advanced or metastatic solid tumors (cancer that has spread) that haven't responded to standard treatments. The drug is designed to target cancer cells while minimizing harm to healthy cells.
Sydney, New South WalesAges 18 years+ - NCT07545122RecruitingPhase 1
Testing CT-202 for Triple Negative Breast, Colorectal, and Bladder Cancers
This early-stage trial tests a new antibody drug called CT-202 in patients whose cancer has come back after standard treatments. The drug is designed to target cancer cells that have a specific protein called Nectin-4, and may help the immune system fight the cancer.
Wahroonga, New South WalesAges 18 years+ - NCT07545759RecruitingPhase 2
Testing brenipatide for IBS with diarrhea symptoms
This study tests whether a new medication called brenipatide can help people with IBS-diarrhea (IBS-D) reduce belly pain and loose stools. IBS-D is a condition where the intestines move too quickly, causing frequent diarrhea and discomfort.
Mesa, ArizonaAges 18–75 - NCT07546812RecruitingPhase 2
Testing Denikitug for advanced stomach and esophageal cancer
This study tests a new drug called denikitug, alone or combined with other cancer treatments, for patients with advanced stomach, gastroesophageal junction, or esophageal adenocarcinoma that has progressed after initial treatment. The drug targets immune cells to help your body fight cancer.
Boston, MassachusettsAges 18 years+
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,599 recruiting gastroenterology studies from the U.S. registry right now, out of 11,991 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.